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Do we need a national antiretroviral treatment register?
Combination antiretroviral therapy (ART) has greatly
improved the prognosis of HIV-infected individuals in affluent
countries, resulting in a marked drop in AIDS-related
mortality.1-3 ART programmes have also been successfully
initiated in less well-resourced health systems. Brazil, a
middle-income developing country, has incorporated ART into
its public health service4 and a successful ART programme has
been implemented in rural Haiti, the poorest country in the
Western hemisphere.5
Results from a South African community clinic-based ART
programme were reported on by Bekker et al. in the June issue
of the Journal.6 Despite the costs of ART, the beneficial impact
on morbidity and mortality has resulted in the World Health
Organisation calling for expanded access to ART in resource-
poor countries.7 While access to ART in South Africa has until
recently been limited largely to the private sector,8 elements of
civil society are now demanding increased access to ART in the
public health sector.9 Recently a costing model of a limited
national ART programme was shown to be affordable10 and
prospects for ART in the South African public sector may have
been further increased with the provisional allocation of R1.9
billion for ART in the 2003 national budget. With 350 000 AIDS
cases in South Africa11 the scale of an ART programme will
need to be of a similar magnitude to that of the TB treatment
programme. Concerns have, however, been raised that
‘Widespread, unregulated access to antiretroviral drugs in sub-
Saharan Africa could lead to a rapid emergence of resistant
viral strains, spelling doom for the individual, curtailing future
treatment options and leading to transmission of resistant
virus’.12 This pessimistic scenario is far from inevitable if a well-
organised national treatment plan is developed. A successful
ART programme will face similar challenges to those of the TB
control programme, where high levels of adherence are
required to a prolonged course of potentially toxic drugs. The
TB control programme utilises a standard two-scheduled
approach to drug therapy, which simplifies the operational
implementation necessary for a large national programme. The
national TB register allows performance assessments to be
made of individual clinics and the programme as a whole.
Similarly a scheduled ART approach would simplify training
and education of medical personnel and would result in
predicable patterns of toxicity and resistance. A predetermined
standardised sequence of drug combinations would also limit
the number of drugs to be procured and managed. 
The major outcomes of a successful ART programme would
be a decrease in AIDS morbidity and mortality. While CD4 cell
counts, clinical stage and viral load determine prognosis of
untreated patients, effective viral suppression by ART is the
major determinant of outcome on treatment. 13 National and
international ART guidelines have been developed and
published which give clear initiation criteria and recommended
therapy combinations, which could be used as a basis for
scheduled drug choice.7.14 A simple register documenting entry
criteria and recording scheduled ART therapy would allow an
overall audit of programme performance in a similar fashion to
that of the TB register. Incorporation of the patient’s national
ID number in conjunction with national death registration data
would allow for calculation of the survival of patients entering
the programme on an ‘intention to treat’ basis. Comparison of
these data with modelled survival of patients determined by
baseline characteristics on entry to the programme would
allow for calculation of life-years gained by the programme. A
national ART programme would utilise large quantities of
relatively expensive drugs and the financial burden of poor
drug accountability could seriously undermine such a
programme. The ART treatment register at any institution
could be reconciled against drug purchases by that institution
for drug accountability purposes and to identify and avoid
‘drug seepage’.  Specific questions such as impact of prior
mother-to-child transmission (MTCT) exposure on response to
ART could be answered by analysis of the register database.
Blood sampling at the time of failure of the first schedule could
also be stored for national viral genotyping surveys, which
could give information on viral resistance patterns, which in
turn would allow scientific-based changes in scheduled drug
choices. 
An ART register would need to be a standardised form that
could be in either paper- or web-based formats. As ART will be
provided at health care facilities other than TB clinics the
administration of the register would need to be the
responsibility of organisations such as national or provincial
AIDS directorates. 
To avoid ART anarchy, it has been suggested that the ART
programme be closely linked and managed within the TB
control programmes of sub-Saharan Africa.12 ART cannot,
however, be isolated from the wider comprehensive approach
to HIV and AIDS patient care, including management of the
psychosocial and other medical complications such as
prophylaxis and treatment of opportunistic infection.7,9 It
would  be neither practical nor prudent to burden the TB
control programme with this heavy responsibility. A scheduled
ART approach could be a useful method to enable wider, more
equitable access to ART within our existing health
infrastructure and an ART register would be a tool to monitor
the overall performance of such an expanded access
programme and allow comparison between sites and delivery
models. While expanded access to ART should not be the
responsibility of the TB clinics there may be important lessons
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to be learned from the programmatic methodological
approaches of the national TB control programme.
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Excessive weight gain following therapy for
hyperthyroidism — a major problem
One of the most characteristic presenting features of
hyperthyroidism is weight loss, despite an increased appetite.
This phenomenon is easily understandable, as hyperthyroidism
is accompanied by a rise in metabolic rate, energy expenditure
and thermogenesis which is clearly not matched by an
increased appetite and caloric intake in the vast majority of
patients.  Consequently a decrease in adipose tissue and
muscle results.  (Curiously a small proportion of hyperthyroid
patients, fewer than 10%, present with weight gain owing to an
increased appetite that exceeds the rise in metabolic rate.1)
Intuitively, one might assume that restoration of thyroid
hormone levels to normal would result in the return of weight
to premorbid levels.  Unfortunately, the insidious presentation
of hyperthyroidism, and inaccurate recall by patients,
complicate a true assessment of premorbid weight.
Nevertheless, just over half of the respondents to a
questionnaire sent to women treated for hyperthyroidism
reported experiencing a weight problem over a mean follow-up
period of 4 years. 2 Furthermore, numerous reports, including
that by Brunova et al.3 in this issue of S A M J (p. 529), corro b o rate
the notion that weight gain following therapy for
hyperthyroidism is frequently excessive.  A mean increase in
weight of between 1.55 and 16.4 kg has been reported
following anti-thyroid therapy.2-6 Indeed, patients attending our
clinic have become aware of this phenomenon, as they
commonly express concern that treating their hyperthyroidism
will lead to excessive weight gain.
Brunova et al. report a retrospective analysis of 160 patients
who were treated for hyperthyroidism; 147 were treated with
radioactive iodine, 3 underwent thyroidectomy and the
remainder received carbimazole. Hypothyroidism ensued in
86.7% of the former two groups and was treated with
thyroxine.3 As the premorbid weight could not be ascertained
accurately, the baseline weight was taken as the weight at
presentation.  Weight gain was noted for 24 months, but it
stabilised thereafter.  The median weight gain found was 5 kg,
6 months after definitive therapy, 9 kg after 12 months and 12
kg after 24 months.  Importantly, 29% of their cohort were
overweight at presentation (body mass index (BMI) > 25
kg/m2) and 19.3% were obese (BMI > 30 kg/m2).  Two years
after treatment, 51.3% had become obese, representing a 32%
increase in the prevalence of obesity.
Notable predictors of weight gain in studies of patients
treated for hyperthyroidism have included a history of weight
loss prior to diagnosis, pre-existing obesity, a diagnosis of
Graves’ disease and the development of hypothyroidism, even
transiently.5 In contrast, patient age, sex and mode of therapy
have not been predictive.2,5 Brunova et al. described similar
major factors associated with increased weight gain, i.e. the
diagnosis of Graves’ disease, need for thyroxine therapy and
poor control of thyroid function on such replacement therapy.3
Yet the extent of weight gain and the rise in the prevalence of
obesity was greater than reported by others.  For example, Dale
and colleagues, who also did not know patients’ premorbid
weight, described a mean weight gain of 5.4 ± 0.5 kg and an
18.5% prevalence of obesity.5 Possible explanations for these
